Make a donation

Research Updates

2018 ASCO Annual Meeting

June 2018

The Annual Meeting brings together more than 32,000 oncology professionals from around the world to discuss the highlights of the latest cancer care treatments, new therapies, and ongoing controversies in the field, via informative and scientific sessions.

Dr. Joseph Mikhael, Chief Medical Officer from the International Myeloma Foundation, presents in the following video an overview of the top multiple myeloma research updates presented at ASCO 2018.

Congratulations to the Recipient of the Jointly Funded 2017 Myeloma Canada and Canadian Research Society Research Grant

September 2017

By analyzing protein from drug-sensitive and drug-resistant myeloma cells, Dr. Chang and his team have discovered a novel protein called pMARCKS (phosphorylated myristoylated alanine-rich C-kinase substrate) that is highly expressed in drug-resistant myeloma cells.


A Second Phase III Study Shows That Carfilzomib (Kyprolis®) Significantly Improves Overall Survival in Patients with Relapsed Multiple Myeloma

August 11, 2017

On July 12, 2017, a press release was issued by Amgen regarding the final overall survival (OS) analysis from the ASPIRE clinical trial evaluating the KRd regimen of carfilzomib (Kyprolis®) in combination with lenalidomide (Revlimid®) and dexamethasone in relapsed myeloma patients. The ASPIRE study demonstrated a significant improvement in the key secondary endpoint of OS. The endpoint of a clinical trial is the goal of the trial; what a trial is trying to measure or find out. Typical endpoints include measurements of toxicity, response rate, and OS.
Results for the study will be presented at a major medical meeting later this year.